Last reviewed: June 22, 2026
Last updated: June 22, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Wegovy, the branded semaglutide injection, follows a 16-week titration schedule starting at 0.25 mg and escalating to a typical maintenance dose of 2.4 mg weekly. However, not all patients require the maximum dose—some achieve meaningful weight loss at 1 mg or 1.7 mg, while others may benefit from staying at intermediate levels. Individual variation in GLP-1 receptor sensitivity, driven partly by genetic factors, explains why one person's effective dose differs from another's.
Standard Wegovy Dosing Protocol and Titration Steps
Wegovy's approved dosing schedule spans 16 weeks and progresses through five incremental steps. Patients begin at 0.25 mg once weekly for four weeks, then advance to 0.5 mg weekly for the next four weeks. The protocol continues with 1 mg weekly (weeks 9–12), followed by 1.7 mg weekly (weeks 13–16), and finally the maintenance target of 2.4 mg weekly. Each step allows the body to adapt to the medication and helps clinicians identify tolerability before increasing further.
The incremental approach minimizes gastrointestinal side effects such as nausea and constipation. Clinical trials show that patients who complete the full titration experience better long-term adherence and sustained weight loss compared to those who skip steps or jump to higher doses prematurely. PlexusDx providers monitor response at each stage and may adjust timing based on individual tolerance and clinical response.
Why Individual Response to Semaglutide Varies by Patient
Not every patient progresses through the entire dosing ladder to reach 2.4 mg, and that is clinically appropriate. Some individuals achieve 10–15% body weight reduction at 1 mg or 1.7 mg and experience diminishing returns or increased side effects at higher doses. This variation stems from differences in GLP-1 receptor density, liver metabolism, and appetite-suppression sensitivity—factors partially influenced by genetic makeup.
The PlexusDx Precision Peptide Genetic Test identifies key variants in the GLP1R gene (rs6923761) and related pathways that influence how individuals respond to semaglutide. Patients with certain genetic profiles may reach their optimal response at a lower dose, while others may require the full 2.4 mg to achieve meaningful satiety and weight loss. Understanding these predispositions helps clinicians personalize dosing decisions and avoid unnecessary escalation.
Maintenance Dosing and Long-Term Weight Management
Once a patient reaches an effective dose, that level typically becomes their maintenance dose—the amount taken weekly for ongoing weight loss and management. The 2.4 mg dose is considered the standard maintenance target in clinical practice, but individual maintenance doses range from 0.5 mg to 2.4 mg depending on response and tolerance. Long-term trials show that patients who maintain consistent dosing experience sustained weight loss and improved cardiometabolic markers over 52–104 weeks.
Maintenance dosing is not fixed for life; some patients experience dose adjustments if weight loss plateaus, side effects emerge, or life circumstances change. PlexusDx compounded semaglutide injection offers flexible dosing at a flat monthly rate starting at $149, ensuring patients can work with their clinician to find and maintain their optimal dose without financial barriers tied to dose escalation.
Comparing Wegovy to Compounded Semaglutide: Dosing and Access
Branded Wegovy and compounded semaglutide use identical active medication and follow the same evidence-based dosing protocols. Both require a prescription, titration oversight, and dose adjustment based on clinical response. The key difference lies in access and cost: Wegovy requires insurance coverage or out-of-pocket payment that scales with dose, while PlexusDx compounded semaglutide injection is available nationwide without insurance and priced at a flat monthly rate—your dose may need to go up, but your price won't.
Compounded semaglutide from licensed 503A pharmacies meets the same pharmaceutical standards as branded medication. Patients using PlexusDx compounded products follow the same 16-week titration schedule and benefit from the same clinical evidence supporting personalized dosing. The added advantage is HSA/FSA eligibility and no membership fees, making consistent, long-term treatment more affordable for patients who need extended therapy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
What is considered a normal or typical Wegovy dose for weight loss?
The typical maintenance dose is 2.4 mg injected once weekly, but many patients achieve significant weight loss at 1 mg, 1.7 mg, or intermediate doses. A 'normal' dose is whatever dose produces meaningful weight loss with tolerable side effects for an individual patient. PlexusDx providers personalize dosing based on clinical response rather than treating 2.4 mg as a one-size-fits-all target.
How long does it take to reach the full Wegovy dose?
The standard titration takes 16 weeks: starting at 0.25 mg and increasing every 4 weeks until reaching the target dose. However, some patients pause at an intermediate dose if they experience adequate weight loss or prefer to minimize side effects. Your clinician may extend the titration timeline if needed for tolerance.
Can I stay on a lower dose of semaglutide if it's working?
Yes, absolutely. Clinical practice supports staying at any dose that achieves your weight loss goals with acceptable side effects. Escalating for the sake of reaching 2.4 mg is not medically necessary if a lower dose delivers results. PlexusDx compounded semaglutide costs the same each month regardless of dose, so there is no financial incentive to use more medication than you need.
What percentage of Wegovy patients reach the 2.4 mg maintenance dose?
Approximately 75–85% of patients in clinical trials complete titration to 2.4 mg, though not all remain on it long-term. Some reduce dose due to side effects, others plateau on lower doses, and some discontinue treatment. Individual response variation is expected and reflects the genetic and metabolic diversity in patient populations.
How does the PlexusDx Precision Peptide Genetic Test improve dosing decisions?
The test identifies genetic variants in the GLP1R, GIPR, FTO, and MC4R genes that influence semaglutide response. Patients with variants associated with higher receptor sensitivity may reach their goal at lower doses, while others may need the full 2.4 mg. This insight helps clinicians avoid under-dosing or over-treating, optimizing both efficacy and safety from the start.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Exploring Higher Doses of Zepbound: What Do They Do?
Is Oral Ozempic as Effective as Injections? A Comprehensive Analysis